Subscribe To
xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-st...
October 31, 2023, 9:15 am
xilio therapeutics announces pipeline and business updates and first quarter 2023 financial results
Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity d...
May 9, 2023, 11:30 am
xilio therapeutics to present at upcoming investor conferences
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnolo...
February 27, 2023, 7:30 am
xilio therapeutics to present at the guggenheim healthcare talks oncology day
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) — xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnol...
February 2, 2023, 12:30 pm
xilio therapeutics to host live virtual program spotlighting xtx301, a tumor-activated il-12
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) — xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnol...
November 23, 2022, 12:30 pm
Nuformix hails progress partner is making with reformulated anti-sickness drug
Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development...
February 8, 2022, 2:57 am
Nuformix hails progress partner is making with reformulated anti-sickness drug
Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development...
February 8, 2022, 2:57 am
Nuformix hails progress partner is making with reformulated anti-sickness drug
Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development...
February 8, 2022, 2:57 am